cycloserine - Profile

What are the generic drug sources for cycloserine and what is the scope of patent protection?

Cycloserine is the generic ingredient in one branded drug marketed by Sanaluz and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for cycloserine

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for cycloserine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanaluz	SEROMYCIN	cycloserine	CAPSULE;ORAL	060593-001	Approved Prior to Jan 1, 1982		RX	No	Yes

Summary

Last updated: February 3, 2026

Cycloserine is an antibiotic primarily indicated for drug-resistant tuberculosis (TB). Its market has expanded with increased global focus on multi-drug resistant TB (MDR-TB). The drug's patent status, regulatory approvals, and manufacturing costs influence its commercial potential. Current market dynamics reflect growing demand in endemic regions and challenges related to toxicity management. Financial projections indicate gradual growth driven by international health initiatives, with limited scope for significant revenue increases absent new formulations or indications.

Market Overview

Aspect	Details
Indication	Multi-drug resistant TB (MDR-TB), approved under WHO guidelines
Approved Regions	U.S., Europe, India, China, and endemic TB regions
Patent Status	Patent expired in most jurisdictions (e.g., EU, US pre-2000s)
Market Size (2022)	Estimated global sales: ~$50 million, primarily in TB-endemic countries
Market Growth Rate	Compound annual growth rate (CAGR) approx. 3-4% over the next five years

Market Dynamics

• Demand Drivers: Rising incidence of MDR-TB in Asia, Africa, and Eastern Europe; WHO prioritizes drug regimens including cycloserine as part of expanded treatment options.
• Supply Factors: Limited number of generic manufacturers; supply chain risks via production costs and regulatory hurdles.
• Regulatory Environment: WHO endorses cycloserine in specific treatment regimens; regulatory approvals in endemic countries facilitate access, often through expedited pathways.
• Pricing and Reimbursement: Low-volume, high-cost treatment; price points typically $10–$50 per pill, varying by region; reimbursement policies influenced by global health funding.

Pharmaceutical and Development Landscape

Company	Product Status	R&D Activity
Seramin Pharmaceuticals	Generic manufacturer in India, active supply	Minimal ongoing R&D; focus on supply stability
Johnson & Johnson	No current proprietary position; previously involved in TB research	N/A
Biotech Startups	Investigate new formulations or delivery systems	Clinical trials for enhanced tolerability

Manufacturing and Cost Structure

• Cost drivers include synthesis complexity, raw material procurement, and regulatory compliance.
• Estimated manufacturing cost per tablet: $0.05–$0.10.
• Patent expiry in key markets diminishes exclusivity; generic competition caps pricing.

Regulatory and Policy Environment

• WHO recommends cycloserine as part of MDR-TB treatment since 2016.
• US FDA approval granted in 1997; no recent updates.
• Endemic countries often adopt drug registration via WHO prequalification; approval timelines average 12–24 months.
• Precautionary measures mandated for toxicity management, specifically neuropsychiatric side effects.

Financial Trajectory and Investment Outlook

Year	Estimated Revenue	Growth Drivers	Risks
2023	~$50 million	Rising MDR-TB cases, health initiatives	Patent expiries, toxicity concerns
2024	~$52 million	Expanded use in endemic regions	Competition from newer drugs
2025	~$55 million	Global health funding increase	Regulatory delays
2026	~$58 million	Improved formulations or dosing	Market saturation

• Limited pipeline activity indicates minimal near-term innovation.
• Investment opportunities hinge on new drug delivery systems or combination therapies.
• Commercial success depends on health policy support and resistance management strategies.

Key Takeaways

• Cycloserine is a niche drug with steady demand driven by MDR-TB prevalence.
• Market growth remains modest; generics and regulatory challenges suppress pricing.
• The primary revenue potential exists in endemic countries receiving international funding.
• R&D investments are focused on improving safety profiles or combination regimens.
• Supply security is critical; few manufacturers dominate global supplies.

FAQs

1. What factors influence cycloserine’s pricing?
   Pricing is affected by manufacturing costs, regional demand, competition from generics, and health policy reimbursements.

2. Are there any new formulations of cycloserine under development?
   Currently, no notable new formulations are in advanced stages; research focuses on toxicity mitigation.

3. How does patent expiry impact the market?
   Patent expiry allows generic manufacturers to enter the market, reducing prices and limiting profit margins for branded versions.

4. What role does the WHO play in cycloserine’s market?
   The WHO's endorsement facilitates procurement in endemic regions and influences regulatory approvals.

5. What are the main risks for investors in cycloserine?
   Risks include market saturation due to generics, toxicity-related treatment limitations, and limited pipeline innovation.

Citations

1. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016.
2. U.S. Food and Drug Administration. Cycloserine approval history.
3. Market research reports. Global Tuberculosis Drugs Market, 2022-2030.
4. Industry interviews and supply chain analyses.
5. Regulatory filings and approval documents from India, China, and EU authorities.